Ligand Pharmaceuticals Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LGND research report →
About the company
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients.
- CEO
- Todd C. Davis
- IPO
- 1992
- Employees
- 68
- HQ
- Jupiter, CA, US
Price Chart
- Market Cap
- $6.40B
- P/E
- 40.76
- P/S
- 23.33
- P/B
- 6.37
- EV/EBITDA
- 30.33
- Div Yield
- 0.00%
- Gross Margin
- 98.61%
- Op Margin
- 36.72%
- Net Margin
- 55.95%
- ROE
- 16.19%
- ROIC
- 5.61%
- Revenue
- $268.09M · 60.40%
- Net Income
- $124.45M · 3186.63%
- EPS
- $6.44 · 3027.27%
- Op Income
- $47.20M
- FCF YoY
- -36.82%
- 52W High
- $320.99
- 52W Low
- $112.83
- 50D MA
- $244.59
- 200D MA
- $207.36
- Beta
- 0.98
- Avg Volume
- 321.46K
Get TickerSpark's AI analysis on LGND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Sabba Stephen L | other | 2,145 |
| Jun 16, 26 | Sabba Stephen L | sell | 2,145 |
| Jun 16, 26 | Sabba Stephen L | other | 2,145 |
| Jun 12, 26 | Haas Jason | other | 1,000 |
| Jun 12, 26 | Haas Jason | other | 3,000 |
| Jun 12, 26 | Haas Jason | sell | 3,000 |
| Jun 12, 26 | Haas Jason | other | 3,000 |
| Jun 12, 26 | Haas Jason | other | 1,000 |
| Jun 12, 26 | Haas Jason | sell | 3,461 |
| Jun 5, 26 | Aryeh Jason | other | 836 |
Our LGND coverage
Recent articles, reports, and earnings notes.
No research on LGND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LGND report →Similar companies
Peers in the same neighborhood.